[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-remodeling\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-remodeling":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100642567","effects-of-icosapent-ethyl-on-coronary-plaque-inflammation-and-ventricular-remodeling-100642567",false,"NCT07641257","Effects of Icosapent Ethyl on Coronary Plaque, Inflammation, and Ventricular Remodeling","Impact of Icosapent Ethyl on Ventricular Remodeling, Inflammation, and Coronary Plaque Stability in Patients With Acute or Chronic Coronary Syndrome: A Prospective, Observational, Real-World Study","Inclusion Criteria:\n\n* Age 18 years and older, of any sex.\n\n  * Definite diagnosis of chronic coronary syndrome (CCS) according to the Chinese Guidelines for the Diagnosis and Management of Patients with Chronic Coronary Syndrome, or acute coronary syndrome (ACS) according to the 2025 ACC\u002FAHA\u002FACEP\u002FNAEMSP\u002FSACI Guideline for the Management of Acute Coronary Syndromes.\n  * Laboratory evaluation showing fasting triglycerides (TG) \\>= 1.7 mmol\u002FL.\n  * Ability to fully understand the study purpose, voluntary participation, and provision of signed written informed consent.\n\nExclusion Criteria:\n\n* Women who are planning a pregnancy, currently pregnant, or lactating.\n\n  * Known hypersensitivity or allergic reaction to the active ingredient of icosapent ethyl (IPE) or any of its excipients (applicable to patients in the exposure cohort).\n  * Diagnosed with major life-threatening conditions such as malignant tumors, end-stage lung disease, or advanced neurodegenerative diseases, with a life expectancy of less than 12 months.\n  * Concurrent participation in any other interventional clinical trial involving investigational drugs or medical devices.\n  * Any other condition or severe non-compliance that, in the judgment of the investigator, makes the patient unsuitable for enrollment in this study.","ALL","18 Years",{"count":19,"type":20},420,"ESTIMATED","12 Months","OBSERVATIONAL","Even with standard treatments like statins, patients with coronary artery disease often face a residual risk of further heart events. This risk is largely driven by ongoing inflammation and unstable fatty plaques in the heart's blood vessels. Icosapent ethyl (IPE) is a highly purified prescription medication known to improve cardiovascular outcomes, but its detailed effects on the heart's structure and inflammation in everyday clinical practice need further exploration.\n\nThis study is a prospective, observational, real-world study designed to evaluate the effectiveness of IPE in patients with Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS). The study plans to enroll 420 patients who will be followed for 12 months. Based on their routine clinical prescriptions, participants will be grouped into a control group (receiving standard cardiovascular care, including statins) and an exposure group (receiving standard care plus IPE).\n\nThroughout the 1-year follow-up, researchers will conduct regular blood tests and advanced heart imaging. The main goal is to determine if adding IPE to standard therapy leads to a more significant reduction in inflammation. Additionally, the study will observe how IPE affects the stability of coronary plaques and the healing process of ventricular remodeling in a real-world clinical setting.",[25,26,27,28,29,30],"Acute Coronary Syndromes (ACS)","Chronic Coronary Syndrome","Coronary Artery Disease","Atherosclerosis Cardiovascular Disease","Ventricular Remodeling","Inflammation","NOT_YET_RECRUITING","2026-06-08",{"date":34,"type":35},"2026-06-11","ACTUAL",{"date":37,"type":20},"2026-05-30",{"date":39,"type":20},"2029-05-30",{"name":41,"class":42},"Ruijin Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100542513","disparities-in-myocardial-infarction-remodeling-according-to-gender-100542513","NCT06343844","Disparities in Myocardial Infarction Remodeling According to Gender","REMOVE 2","Inclusion Criteria:\n\n* Age \\> 18 years\n* First myocardial infarction with ST-segment elevation during the hospital phase\n* Coronary angiography performed within 72 hours of the infarction\n* Inclusion in the RIMA registry\n* Patient affiliated or beneficiary of a social security scheme; Signature of informed consent\n\nExclusion Criteria:\n\n* Patients already enrolled in the study\n* Poor understanding of the French language\n* Pregnant, breastfeeding, or postpartum women\n* Individuals deprived of liberty by judicial or administrative decision; Individuals receiving psychiatric care under coercion\n* Individuals subject to a legal protection measure; Individuals incapable of giving consent",{"count":51,"type":20},1650,"INTERVENTIONAL",[54],"NA","Following myocardial infarction, female individuals demonstrate a poorer prognosis, characterized by elevated rates of mortality and heart failure. A primary hypothesis suggests unfavorable cardiac remodeling in women. This remodeling, defined as alterations in cardiac size and shape post-infarction, necessitates repeated non-invasive imaging for study.",[57,29],"Myocardial Infarction",[59,60],"Non-Interventional Registry","Biorepository Establishment","RECRUITING","2026-02-06",{"date":64,"type":35},"2026-02-09",{"date":66,"type":35},"2024-07-15",{"date":68,"type":20},"2040-09-01",{"name":70,"class":71},"University Hospital, Angers","OTHER_GOV",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":72},"100551724","effect-of-recombinant-human-brain-natriuretic-peptide-on-ventricular-remodeling-and-cardiac-function-in-patients-with-acute-anterior-myocardial-infraction-undergoing-percutaneous-coronary-intervention-100551724","NCT06463808","Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention","Inclusion Criteria:\n\n1. The first acute anterior myocardial infarction ( AMI ) within 12 hours ( or more than 12 hours but the ischemic symptoms continue ).\n2. Age 18-75 years old, gender unlimited\n3. Patients with acute anterior myocardial infarction undergoing emergency PCI within the effective time window\n4. Successful reflow after interventional therapy ( TIMI = 3 ).\n5. To understand and sign the informed consent.\n\nExclusion Criteria：\n\n1. Patients with a history of coronary artery bypass grafting\n2. Patients with cardiogenic shock\n3. Patients with systolic blood pressure ( SBP ) ≤ 90 mmHg after treatment with vasopressors\n4. Patients with mechanical complications ( ventricular septal perforation, mitral chordae rupture )\n5. Patients with suspected aortic dissection\n6. Patients with severe liver and kidney dysfunction\n7. Allergic or intolerant to rhBNP.\n8. Patients with chronic renal insufficiency requiring long-term dialysis\n9. Patients using diuretics during the screening period\n10. Pregnant \u002F lactating women\n11. Heart diseases that are not suitable for vasodilators, such as severe valve stenosis, restrictive cardiomyopathy, restrictive pericarditis, etc","75 Years",{"count":81,"type":20},100,"This study is designed to evaluate the efficacy and safety of Recombinant Human Brain Natriuretic Peptide (rhBNP) in improving ventricular remodeling and cardiac function after acute anterior myocardial infarction undergoing percutaneous coronary intervention. 100 patients with acute anterior myocardial infarction after primary Percutaneous Coronary Intervention (pPCI) are randomly assigned 1:1 to rhBNP group(n=50) and control group(n=50) with follow-up of 24 weeks. Both groups are treated with standard therapy of AAMI, with the rhBNP group intravenous dripping rhBNP after pPCI for 3 days and the control group treated with placebo at the same time. The primary endpoint is the change in N terminal pro-B-type natriuretic peptide（NT-proBNP ）and cardiac troponin T(cTnT) level.The secondary endpoint is the change in 24-week echocardiographic including left ventricle ejection fraction (LVEF) , left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index (LVESVI), arrhythmia and cardiovascular events (death, cardiac arrest or cardiopulmonary resuscitation, hospitalization due to heart failure or angina pectoris).",[29,84],"Myocardial Infarction, Anterior Wall",[84,86,29,87],"Recombinant Human Brain Natriuretic Peptide","Percutaneous Coronary Intervention","2024-06-16",{"date":90,"type":35},"2024-06-18",{"date":92,"type":35},"2023-05-03",{"date":94,"type":20},"2025-02-28",{"name":96,"class":42},"The First Affiliated Hospital with Nanjing Medical University"]